Zurcher Kantonalbank Zurich Cantonalbank Purchases 1,237 Shares of Humana Inc. (NYSE:HUM)

Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Humana Inc. (NYSE:HUMFree Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,880 shares of the insurance provider’s stock after buying an additional 1,237 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Humana were worth $21,004,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Mariner LLC grew its stake in Humana by 2.3% during the third quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock worth $6,869,000 after buying an additional 312 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Humana by 27.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider’s stock worth $13,595,000 after buying an additional 6,034 shares during the last quarter. Silverarc Capital Management LLC bought a new stake in Humana during the third quarter worth about $4,865,000. Vest Financial LLC grew its stake in shares of Humana by 43.3% during the fourth quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock valued at $12,815,000 after purchasing an additional 8,455 shares during the last quarter. Finally, Artemis Investment Management LLP grew its stake in shares of Humana by 9.6% during the fourth quarter. Artemis Investment Management LLP now owns 64,573 shares of the insurance provider’s stock valued at $29,563,000 after purchasing an additional 5,672 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Trading Up 1.9 %

HUM opened at $323.46 on Thursday. The firm’s fifty day moving average is $344.41 and its two-hundred day moving average is $425.71. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The firm has a market cap of $39.03 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.45. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21.

Humana (NYSE:HUMGet Free Report) last posted its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The firm had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter last year, the business posted $1.62 earnings per share. Equities research analysts anticipate that Humana Inc. will post 16.06 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.09%. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Bank of America reissued a “neutral” rating and set a $342.00 price target (down from $470.00) on shares of Humana in a research note on Tuesday, April 2nd. TheStreet cut shares of Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. TD Cowen decreased their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. The Goldman Sachs Group decreased their price target on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Finally, Raymond James began coverage on shares of Humana in a research note on Friday, March 22nd. They issued a “market perform” rating on the stock. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $465.42.

View Our Latest Stock Analysis on Humana

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.